42.31  0.29 (0.69%)		09-21 14:54
Open: 41.87 High: 42.5199 Volume: 394,459		Pre. Close: 42.02 Low: 41.2 Market Cap: 2,449(M)

Short term
Mid term
Targets	6-month :	50.79	1-year :	59.33
Resists	First :	43.49	Second :	50.79
Pivot price	41.77
Supports	First :	39.77	Second :	37.47
MAs	MA(5) :	42.23	MA(20) :	41.14
	MA(100) :	35.82	MA(250) :	33.67
MACD	MACD :	1	Signal :	1.1
%K %D	K(14,3) :	72.8	D(3) :	74.6
RSI	RSI(14): 59.9
52-week	High :	43.49	Low :	25.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ HRMY ] has closed below upper band by 41.9%. Bollinger Bands are 31.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	43.3 - 43.52	43.52 - 43.66
Low:	41.44 - 41.73	41.73 - 41.91
Close:	41.61 - 42.04	42.04 - 42.32

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Sat, 19 Sep 2026
Harmony Biosciences CMO sells $1.65m in shares By Investing.com - Investing.com South Africa

Fri, 18 Sep 2026
Harmony Biosciences (HRMY) CMO exercises options and sells shares - Stock Titan

Fri, 18 Sep 2026
$1.5M stock sale planned by Harmony Biosciences (NASDAQ: HRMY) officer - Stock Titan

Thu, 17 Sep 2026
After preset plan trades, Harmony Biosciences (NASDAQ: HRMY) officer plans 800-share sale - Stock Titan

Thu, 17 Sep 2026
Harmony Biosciences Holdings, Inc. - Common Stock (Nasdaq:HRMY) Price Chart - The Chronicle-Journal

Wed, 16 Sep 2026
Officer stock sale at Harmony Biosciences (NASDAQ: HRMY) follows earlier 10b5-1 trades - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	58 (M)
Shares Float	52 (M)
Held by Insiders	11.6 (%)
Held by Institutions	99.7 (%)
Shares Short	4,140 (K)
Shares Short P.Month	5,110 (K)

EPS	3.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	17.19
Profit Margin	18.8 %
Operating Margin	34.1 %
Return on Assets (ttm)	11.6 %
Return on Equity (ttm)	20.4 %
Qtrly Rev. Growth	30.2 %
Gross Profit (p.s.)	12.43
Sales Per Share	16.48
EBITDA (p.s.)	4.39
Qtrly Earnings Growth	88.1 %
Operating Cash Flow	355 (M)
Levered Free Cash Flow	183 (M)

PE Ratio	13.6
PEG Ratio	0
Price to Book value	2.44
Price to Sales	2.55
Price to Cash Flow	6.89

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.